- Home
- SPFI vs GOSS Comparison
SPFI vs GOSS Comparison
Compare SPFI & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPFI | GOSS |
|---|---|---|
| Founded | 1941 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 614.0M | 726.8M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SPFI | GOSS |
|---|---|---|
| Price | $39.28 | $3.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $41.50 | $8.60 |
| AVG Volume (30 Days) | 40.2K | ★ 2.9M |
| Earning Date | 01-23-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | ★ 36.91 | N/A |
| EPS | ★ 3.51 | N/A |
| Revenue | ★ $205,251,000.00 | $44,051,000.00 |
| Revenue This Year | $13.52 | N/A |
| Revenue Next Year | $6.28 | $16.11 |
| P/E Ratio | $11.26 | ★ N/A |
| Revenue Growth | ★ 11.60 | N/A |
| 52 Week Low | $30.01 | $0.67 |
| 52 Week High | $42.38 | $3.60 |
Technical Indicators
Market Signals| Indicator | SPFI | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 61.16 | 64.14 |
| Support Level | $37.39 | $2.98 |
| Resistance Level | $38.55 | $3.45 |
| Average True Range (ATR) | 0.83 | 0.23 |
| MACD | 0.20 | 0.03 |
| Stochastic Oscillator | 89.58 | 93.69 |
Price Performance
Historical ComparisonAbout SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.